Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: A single institutional experience

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 6, 2012, Pages 530-536

  Kinsella, Mary Diane ^a   Nassar, Aziza ^b   Siddiqui, Momin T ^a   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Breast; ER; HER2; Immunohistochemistry; Neoadjuvant; PR

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CORE NEEDLE BIOPSY; LUNG CARCINOMA; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866046485     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Mamounas EP. NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res 2003; 4: 309-326.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
3. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11: 4-12.
4. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
5. Arens N, Bleyl U, Hildenbrand R. Her2Neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virch Arch 2005; 446: 489-496.
6. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma. Breast J 2008; 14: 141-146.
7. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M, Jakesz R. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 2003; 10: 91-98.
8. Kasami M, Uematsu T, Honda M. Yabuzaki T, Sanuki J, Uchida Y, Sugimura H. Comparison of estrogen receptor, progesterone receptor, and Her-2 status in breast cancer pre- and post- neoadjuvant chemotherapy. Breast 2008; 17: 523-527.
9. Varga Z, Caduff R, Pestalozzi B. Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 2005; 446: 136-141.